The European Commission and European Medicines Agency’s updated the guidance on managing clinical trials conducted during the COVID-19 pandemic by expanding the use and scope of remote source data verification (rSDV) in clinical trials.
While previous versions of the guidance stated that rSDV would “only be considered necessary for very few trials” involving the treatment or prevention of COVID-19, “Or in the final data cleaning steps before database lock in pivotal trials investigating serious or life-threatening conditions with no satisfactory treatment option.”, the updated guidance has expanded the types of trials that may use rSDV.

According to the guidance, rSDV can be used for trials:

  • involving the treatment or prevention of COVID-19
  • investigating serious or life-threatening conditions
  • pivotal trials
  • “where the absence of SDV for critical data may likely pose unacceptable risks to participants’ safety or the reliability/integrity of trial results”
  • “involving particularly vulnerable participants such as children or those temporarily […] or permanently […] incapable of giving their informed consent.”

Moreover, the updated Annex 1 clarifies that the principal investigator (PI), the PI’s institution and the sponsor may be jointly responsible as controllers for ensuring that participants’ information is safeguarded.

For more details, please see the official guidance from the EMA and the European Commission.

Meditrial has developed rapid workflows to conduct risk assessment, implement rescue plans and execute solutions for ongoing clinical trials: